Green Fresh Biotechnology Company Limited

Green Fresh Biotechnology Company Limited

HHKEX:1084
0.63
HKD
+0.00
(-0.79%)
620.63MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.54
0.58
0.96
1.24
0.77
1.16
1.71
1.42
1.18
1.05
- -
Basic EPS, GAAP
0.05
0.08
0.09
0.12
0.06
0.1
0.24
-0.1
0.07
0.01
- -
Free Cash Flow per Basic Share
0.02
-0.03
-0.02
-0.08
-0.04
-0.02
-0.08
0.1
0.1
-0.02
- -
Dividend per Share
- -
- -
- -
- -
0.05
0.03
0.04
0.03
- -
0.01
- -
Book Value per Share
0.15
0.27
0.39
0.7
0.65
0.84
1.02
0.9
0.96
0.97
0.96
Tangible Book Value per Share
0.08
0.18
0.28
0.59
0.55
0.68
0.87
0.75
0.82
0.83
0.82
Basic Weighted Avg Shares
800
800
800
641
806
819
823
828
836
863
832
Sales/Revenue/Turnover
429
460
769
797
622
951
1,411
1,174
989
905
- -
Operating Margin (%)
15.91
18.76
16.04
15.87
12.58
14.55
20.58
-6.22
11
4.12
- -
Depreciation Expense
14
16
31
33
31
43
50
47
48
47
- -
Net Income, GAAP
43
65
72
75
49
85
199
-85
62
7
- -
Effective Tax Rate (%)
25.65
22.98
27.74
26.97
23.56
24.49
23.58
- -
24.73
24.62
- -
Profit Margin (%)
9.98
14.02
9.39
9.4
7.86
8.91
14.12
-7.27
6.28
0.73
- -
Working Capital
-66
-23
55
248
193
264
430
300
443
450
443
LT Debt
51
83
93
50
25
82
91
69
103
102
103
Total Equity
122
214
314
564
535
705
852
754
850
847
850
Return on Invested Capital (%)
- -
17.77
16.41
12.16
6.83
9.37
16.55
- -
5.96
1.82
- -
Return on Capital (%)
- -
18.26
16.72
12.24
7.15
9.34
16.56
- -
6.2
1.99
- -
Return on Common Equity (%)
- -
38.45
27.38
17.08
8.95
13.91
25.99
-10.73
7.84
0.78
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
533
527
462
LT Borrowings
67
59
101
LT Finance Leases
2
3
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
830
834
874
Market Capitalization
573
613
583

Working Capital

CNY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
997
974
1,039
Cash, Cash Equivalents & STI
73
65
121
Accounts Receivable, Net
85
98
113
Inventories
785
766
748
Total Current Liabilities
697
645
596
Payables & Accruals
- -
- -
- -
ST Debt
533
527
462
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
10.71%
-0.36%
Free Cash Flow
- -
1.41%
-123.69%
Net Income, GAAP
- -
-39.31%
-89.4%
Sales/Revenue/Turnover
- -
12.03%
-8.55%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1,174
2024
- -
- -
989
2025
- -
- -
905

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.1
2024
- -
- -
0.07
2025
- -
- -
0.01

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.03
2024
- -
- -
- -
2025
- -
- -
0.01

Company Description

CEO
Kam Chung Chan
Full Time Employees
1,168
Sector
Consumer non-durables
Industry
Food: major diversified
Address
Flat A Hong Kong Hong Kong
IPO Date
Oct 17, 2019
Business
Green Fresh Biotechnology Company Limited engages primarily in the production and sale of seaweed-based and plant-based hydrocolloid products in China and overseas markets. Its core product portfolio includes agar-agar products, carrageenan products, konjac products, and blended products derived from natural seaweed and plant sources, which are widely used as food additives in dairy products, beverages, confectioneries, meat products, jellies, and desserts. The company also produces other related products such as algae powder. Founded in 2001 and headquartered in Hong Kong, Green Fresh Biotechnology operates through subsidiaries in China, including Green Fresh (Fujian) Foodstuff Co., Ltd. The company maintains a strong research and development capability with an independent R&D center focused on innovation and enhancement of product quality and profitability. In recent years, Green Fresh Biotechnology undertook a significant rebranding and name change from Green Future Food Hydrocolloid Marine Science Company Limited to its current name, effective July 2025. This change reflects a strategic shift to better align the brand with its core biotechnology focus. The company has also expanded its product offerings to higher value-added blended products and developed fast-dissolvable agar for use in dairy and health foods, alongside new markets for gel-type air fresheners and beauty products such as face masks. Additionally, Green Fresh is investing in production facility enhancements to improve product quality, cost competitiveness, and sustainability. The company emphasizes the development of 100% bio-based products and is dedicated to leveraging advanced biotechnology to sustain growth and improve returns on investment. Green Fresh Biotechnology operates primarily within the specialty chemicals and materials sector, serving food processing industries with natural hydrocolloid solutions. Its major markets include China and selected overseas regions in Europe. The company's strategic initiatives, including its rebranding and ongoing product innovation, position it to capitalize on the growing demand for natural, high-quality food additives and related biotechnology products. Its controlling shareholders include prominent figures such as Mr. Chan Kam Chung and Mr. Chan Shui Yip, under whose leadership the company continues to pursue technical excellence and market expansion. This comprehensive product range, coupled with recent strategic realignments and R&D investments, reinforces Green Fresh Biotechnology's status as a leading producer of hydrocolloid products in China with expanding global outreach.